Literature DB >> 20097098

Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma.

Antonio Nicolini1, Laura Martinetti, Silvia Crespi, Marco Maggioni, Angelo Sangiovanni.   

Abstract

PURPOSE: To retrospectively compare radiologic tumor response and degree of necrosis in explanted livers after chemoembolization with epirubicin-loaded DC Bead versus bland embolization in patients on a transplant waiting list.
MATERIALS AND METHODS: From 2003 to 2007, 49 patients with hepatocellular carcinoma (HCC) underwent transplantation at a single center. Sixteen patients were treated with bland embolization (n = 8) with 100-300-microm Embosphere particles or chemoembolization with epirubicin-loaded 100-300-microm DC Bead particles (n = 8) every other month until complete tumor devascularization. Computed tomography was performed every 3 months until recurrence. Explanted livers were analyzed to evaluate the degree of necrosis in the nodules. After orthotopic liver transplantation (OLT), patients were followed up for survival and disease status.
RESULTS: The groups were comparable for baseline characteristics. Most patients had Child-Pugh class A disease. Solitary HCC was found in 75% of patients. Mean target lesion size was 32 mm +/- 15.4. Chemoembolization with drug-eluting beads achieved complete necrosis in 77% of lesions whereas bland embolization achieved complete necrosis in 27.2% of lesions. There was a significant difference between bland embolization and chemoembolization with DC Bead with regard to histologic necrosis (P = .043). No significant treatment-related complications were observed for either group. Fifteen patients are alive with no tumor recurrence.
CONCLUSIONS: Chemoembolization with drug-eluting beads before OLT achieved higher rates of complete histologic response than bland embolization, with no serious adverse events observed. Because of the retrospective data analyses and small sample size, further studies are warranted to confirm these promising results. Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097098     DOI: 10.1016/j.jvir.2009.10.038

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  39 in total

Review 1.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

Review 2.  Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Authors:  Thierry de Baere; Lambros Tselikas; Frederic Deschamps; Valerie Boige; Michel Ducreux; Antoine Hollebecque
Journal:  Hepat Oncol       Date:  2016-03-23

Review 3.  Chemoembolization with DC Bead™ for the treatment of hepatocellular carcinoma: an update.

Authors:  Katerina Malagari; Emmanouil Emmanouil; Maria Pomoni; Dimitrios Kelekis
Journal:  Hepat Oncol       Date:  2014-03-20

4.  Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.

Authors:  Bruno C Odisio; Aaron Ashton; Yuanqing Yan; Wei Wei; Ahmed Kaseb; Michael J Wallace; Jean N Vauthey; Sanjay Gupta; Alda L Tam
Journal:  J Vasc Interv Radiol       Date:  2015-06-05       Impact factor: 3.464

5.  Locoregional treatment for hepatocellular carcinoma: The best is yet to come.

Authors:  Naveen Kalra; Pankaj Gupta; Yogesh Chawla; Niranjan Khandelwal
Journal:  World J Radiol       Date:  2015-10-28

Review 6.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

7.  Updates in the management of hepatocellular carcinoma.

Authors:  Robert Wong; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

Review 8.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 9.  Chemoembolization of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Pasquale Petruzzi; Laura Crocetti
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 10.  Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.

Authors:  Jia-Yan Ni; Lin-Feng Xu; Wei-Dong Wang; Hong-Liang Sun; Yao-Ting Chen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.